Impact of LTBI Treatment on Glucose Tolerance and Chronic Inflammation

NCT04830462 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

32

Enrollment

OTHER

Sponsor class

Conditions

Latent Tuberculosis
Diabetes Mellitus, Type 2

Interventions

DRUG: Rifampicin 300 Mg Oral Capsule
DRUG: Isoniazid 300 Mg ORAL TABLET

Sponsor

Herlev and Gentofte Hospital